Skip to Content

Our Network

EndPoints is made up of centers of excellence in clinical research, with a presence across various regions of Latin America. Each center contributes local expertise, robust infrastructure, and a shared commitment to public health, ethics, and operational quality.

CEVAXIN

Location: Panama City

Specialties: Vaccines, infectious diseases, respiratory, HIV, HPV, pneumococcus, RSV

Key infrastructure:

  • Medical offices, in-house pharmacy, and laboratory
  • Monitoring room and informed consent facilities
  • Real-time management platform

Completed studies:

  • 60+ clinical trials
  • 20,000+ participants
  • Pediatric, adult, and pregnant populations
  • Contributions to 10+ vaccines now approved
Visit Site

CEIP

Location: Cali, Colombia

Specialties: Vaccines, infectious diseases, maternal-child health, community-based studies

Key infrastructure:

  • 14 consultation rooms, pharmacy, laboratory, and call center
  • Resuscitation room and auditorium
  • 85 °C freezers, cold storage units, and redundant connectivity systems

Completed studies:

  • 50+ clinical trials
  • 28,000+ enrolled participants
  • Contributions to 15+ approved vaccines
Visit Site

CECLISA

Location: Guatemala City

Specialties: Vaccines, pediatrics, respiratory diseases, gastroenterology

Key infrastructure:

  • Pediatric and adult consultation rooms
  • Laboratory with sample processing and PBMC capabilities
  • Procedure and observation rooms
  • 70 °C freezers and validated cold chain

Completed studies:

  • 20+ clinical trials
  • Participation in phase II and III studies, including pediatric and COVID-19 vaccine trials
Visit Site

PSN

Location: Bogotá (Usaquén), Colombia

Specialties: Vaccines, gastroenterology, respiratory health

Key infrastructure:

  • Private IPS with over 30 years of clinical experience
  • Research center approved by INVIMA
  • Electronic medical records and fast-track enrollment capability

Completed studies:

  • 6+ clinical trials since 2021
  • Record-setting enrollment in COVID-19 and RSV studies
Visit Site